Page last updated: 2024-11-08

pentylenetetrazole and Insulin Resistance

pentylenetetrazole has been researched along with Insulin Resistance in 1 studies

Pentylenetetrazole: A pharmaceutical agent that displays activity as a central nervous system and respiratory stimulant. It is considered a non-competitive GAMMA-AMINOBUTYRIC ACID antagonist. Pentylenetetrazole has been used experimentally to study seizure phenomenon and to identify pharmaceuticals that may control seizure susceptibility.
pentetrazol : An organic heterobicyclic compound that is 1H-tetrazole in which the hydrogens at positions 1 and 5 are replaced by a pentane-1,5-diyl group. A central and respiratory stimulant, it was formerly used for the treatment of cough and other respiratory tract disorders, cardiovascular disorders including hypotension, and pruritis.

Insulin Resistance: Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Sedky, AA1
El Serafy, OMH1
Hassan, OA1
Abdel-Kawy, HS1
Hasanin, AH1
Raafat, MH1

Other Studies

1 other study available for pentylenetetrazole and Insulin Resistance

ArticleYear
Trimetazidine potentiates the antiepileptic activity and ameliorates the metabolic changes associated with pentylenetetrazole kindling in rats treated with valproic acid.
    Canadian journal of physiology and pharmacology, 2017, Volume: 95, Issue:6

    Topics: Animals; Anticonvulsants; Aorta; Biomarkers; Blood Glucose; Drug Synergism; Epilepsy; Hippocampus; I

2017